Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D; TRANSCENDS Group; Gray D, Lieberman J. Abi-Dargham A, et al. Schizophr Bull. 2022 Jan 21;48(1):199-210. doi: 10.1093/schbul/sbab095. Schizophr Bull. 2022. PMID: 34423843 Free PMC article.
Illness Phase as a Key Assessment and Intervention Window for Psychosis.
Kohler CG, Wolf DH, Abi-Dargham A, Anticevic A, Cho YT, Fonteneau C, Gil R, Girgis RR, Gray DL, Grinband J, Javitch JA, Kantrowitz JT, Krystal JH, Lieberman JA, Murray JD, Ranganathan M, Santamauro N, Van Snellenberg JX, Tamayo Z; TRANSCENDS Group; Gur RC, Gur RE, Calkins ME. Kohler CG, et al. Biol Psychiatry Glob Open Sci. 2022 Jun 18;3(3):340-350. doi: 10.1016/j.bpsgos.2022.05.009. eCollection 2023 Jul. Biol Psychiatry Glob Open Sci. 2022. PMID: 37519466 Free PMC article. Review.
A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.
Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam S, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray DL, Grinband J, Gur RC, Haubold NK, Heffernan Z, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro NP, Schutte CT, Selloni A, Van Snellenberg J, Surti T, Wolf DH, Zharyy C; TRANSCENDS Group; Abi-Dargham A, Gur RE, Lieberman JA, Kantrowitz JT, Anticevic A, Cho YT, Krystal JH. Fonteneau C, et al. medRxiv [Preprint]. 2025 Apr 20:2025.04.18.25326082. doi: 10.1101/2025.04.18.25326082. medRxiv. 2025. PMID: 40321245 Free PMC article. Preprint.